FENC

Investors need to pay close attention to FENC stock based on the movements in the options market lately.

RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.

RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on May 11, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of stock option awards (“Stock Options”) to purchase an aggregate of 50,000 of the Company's common shares to three new non-executive employees of the Company with a grant date of May 18, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The Stock Options consist of incentive stock options to purchase an aggregate of 49,141 shares and nonqualified stock options to purchase an aggregate of 859 shares. The Stock Options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript

Adherex Technologies NASDAQ: FENC executives said Fennec Pharmaceuticals entered 2026 with stronger commercial momentum for PEDMARK, reporting higher first-quarter sales, positive operating cash flow and early signs that recent sales force investments are increasing demand.

Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.04 per share a year ago.

~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK ® Demand in April 2026 ~ ~ Initiated Third Institution-Led Clinical Study Evaluating PEDMARK ® in Adolescent and Young Adult (AYA) and Adult Patients with Head and Neck and Testicular Cancers ~ ~ Four Abstracts Evaluating PEDMARK ® will be Included in the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Program ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C.

RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, May 14, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results.

~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK ® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~

San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fennec Pharmaceuticals Inc. (NASDAQ: FENC). The investigation focuses on Fennec Pharmaceuticals executive officers and whether investor losses may be recovered under federal securities laws.